| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1From the Department of Ophthalmology, School of Medicine, University of California, Irvine, California; the 2Department of Ophthalmology, The Ross Eye Institute, and the 3Department of Physiology and Biophysics, The State University of New York, Buffalo, New York.
PURPOSE. To study the toxicity of triamcinolone acetonide (Kenalog; Bristol-Meyers Squibb, Princeton, NJ) on retinal pigment epithelial (ARPE-19) and retinal neurosensory (R28) cells.
METHODS. ARPE-19 and R28 were grown in tissue culture in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum. Cells were treated with 50, 100, and 200 µg/mL concentration of triamcinolone acetonide for 2, 6, and 24 hours. The cells were also treated with the steroid without the vehicle and with the vehicle alone, in which triamcinolone acetonide was suspended. Toxicity was determined by trypan blue dye-exclusion and WST-1 mitochondrial dehydrogenase assays.
RESULTS. Vehicle alone did not reduce the viability of ARPE-19 or R28 cells and also did not affect the mitochondrial dehydrogenase activity of the cells. The mean cell viability of ARPE-19 and R28 cells after exposure to triamcinolone acetonide with vehicle 200 µg/mL for 24 hours was 70.7% ± 10.61% and 75.35% ± 12.42%, respectively compared with the untreated ARPE-19 (92.7% ± 6.24%, P < 0.01) and R28 cells (90.63% ± 5.62%, P < 0.001). The mean cell viability of ARPE-19 cells after exposure to triamcinolone acetonide (200 µg/mL) alone without the vehicle was 84.96% ± 0.32%, 85.2% ± 3.26%, and 84.73% ± 2.71% at 2, 6, and 24 hours, respectively, compared with the untreated ARPE-19 cells (P < 0.001). The R28 cells exposed to triamcinolone acetonide (200 µg/mL) without the vehicle also had a significant reduction in the mean cell viability at 24 hours (86.42% ± 3.87%, P < 0.001) and 6 hours (89.03% ± 1.01%, P < 0.01). There was a significant reduction in the mitochondrial dehydrogenase activity in the ARPE-19 cells when treated with both triamcinolone acetonide, with or without the vehicle at a concentration of 200 µg/mL at all time points (P < 0.01). R28 cells did not have any significant reduction in mitochondrial dehydrogenase activity when treated with triamcinolone acetonide without the vehicle at any of the doses, but there was a significant reduction when the R28 cells were treated with triamcinolone acetonide with vehicle (200 µg/mL) for 24 hours (P < 0.05). Triamcinolone acetonide with vehicle caused a greater reduction in cell viability and mitochondrial dehydrogenase activity than did triamcinolone without vehicle, in both cell lines, although the difference was not statistically significant.
CONCLUSIONS. Triamcinolone acetonide is toxic to proliferating cells of retinal origin in vitro at doses normally used in clinical practice. The vehicle by itself appears to be nontoxic to the cells, but may have a potentiating effect on the cytotoxicity of triamcinolone acetonide. The results of this in vitro study cannot be directly extrapolated to clinical practice, but, based on these data, further studies may be warranted.
This article has been cited by other articles:
|
|
 |
|
  G Weigert, S Michels, S Sacu, A Varga, F Prager, W Geitzenauer, and U Schmidt-Erfurth Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study Br. J. Ophthalmol., March 1, 2008; 92(3): 356 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lorenzo Carrero, M. Gonzalez Barcia, and I. Perez Flores Sterile Endophthalmitis After Benzyl Alcohol Filtered Triamcinolone Acetonide Injection Arch Ophthalmol, January 1, 2008; 126(1): 142 - 143. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Chung, J. J. Hwang, J. Y. Koh, J.-g. Kim, and Y. H. Yoon Triamcinolone Acetonide-Mediated Oxidative Injury in Retinal Cell Culture: Comparison with Dexamethasone Invest. Ophthalmol. Vis. Sci., December 1, 2007; 48(12): 5742 - 5749. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Kozak, L. Cheng, G. A. Silva, and W. R. Freeman Testing of Intraocular Drugs for Clinical Use Invest. Ophthalmol. Vis. Sci., November 1, 2007; 48(11): 4861 - 4863. [Full Text] [PDF]
|
|
|
|
|
|
Y.-S. Chang, C.-L. Wu, S.-H. Tseng, P.-Y. Kuo, and S.-Y. Tseng Cytotoxicity of Triamcinolone Acetonide on Human Retinal Pigment Epithelial Cells Invest. Ophthalmol. Vis. Sci., June 1, 2007; 48(6): 2792 - 2798. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Scorolli, M. Morara, A. Meduri, L. B. Reggiani, G. Ferreri, S. Z. Scalinci, and R. A. Meduri Treatment of Cystoid Macular Edema in Retinitis Pigmentosa With Intravitreal Triamcinolone Arch Ophthalmol, June 1, 2007; 125(6): 759 - 764. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R Obata, A Iriyama, Y Inoue, H Takahashi, Y Tamaki, and Y Yanagi Triamcinolone acetonide suppresses early proangiogenic response in retinal pigment epithelial cells after photodynamic therapy in vitro Br. J. Ophthalmol., January 1, 2007; 91(1): 100 - 104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Hartnett, D. J. Martiniuk, Y. Saito, P. Geisen, L. J. Peterson, and J. R. McColm Triamcinolone Reduces Neovascularization, Capillary Density and IGF-1 Receptor Phosphorylation in a Model of Oxygen-Induced Retinopathy Invest. Ophthalmol. Vis. Sci., November 1, 2006; 47(11): 4975 - 4982. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
